Trial in Progress: REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase Ib Multi-Cohort Study of Combination Regimens for Patients with Relapsed/Refractory Multiple Myeloma

被引:3
|
作者
Rodriguez Otero, Paula [1 ]
Joseph, Nisha S. [2 ]
Kumar, Shaji K. [3 ]
Lee, Hans C. [4 ]
Leleu, Xavier [5 ]
Manier, Salomon [6 ]
Dimopoulos, Meletios A. [7 ]
Victoria Mateos, Maria [8 ]
Oriol, Albert [9 ,10 ]
Bumma, Naresh [11 ,12 ]
Gong, Weiying [13 ]
Roy, Pourab [13 ]
Lorenc, Karen Rodriguez [13 ]
Kroog, Glenn S. [13 ]
Sarkaria, Shawn M. [13 ]
机构
[1] Clin Univ Navarra, Dept Hematol, Pamplona, Spain
[2] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Louisville, KY USA
[3] Mayo Clin, Rochester, MN USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Ctr Hosp Univ Poitiers, Poitiers, France
[6] CHRU Lille, Lille, France
[7] Alexandra Gen Hosp Athens, Athens, Greece
[8] Hosp Clin Univ Salamanca, Salamanca, Spain
[9] Hosp Germans Trias i Pujol, Inst Catala Oncol, Badalona, Spain
[10] Hosp Germans Trias i Pujol, Inst Josep Carreras, Badalona, Spain
[11] Ohio State Univ, James Canc Hosp, Columbus, OH 43210 USA
[12] Solove Res Inst, Columbus, OH USA
[13] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
关键词
D O I
10.1182/blood-2022-157713
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:4444 / 4446
页数:3
相关论文
共 50 条
  • [1] Trial in progress: linvoseltamab, a BCMAxCD3 bispecific antibody, in a Phase 1b multi-cohort study of combination regimens for patients with relapsed/refractory multiple myeloma
    Rodriguez-Otero, Paula
    Joseph, Nisha
    Kumar, Shaji
    Leleu, Xavier
    Manier, Salomon
    Dimopoulos, Meletios
    Mateos, Maria-Victoria
    Oriol, Albert
    Bumma, Naresh
    Gong, Weiying
    Roy, Pourab
    Lorenc, Karen Rodriguez
    Kroog, Glenn
    Sarkaria, Shawn
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S60 - S60
  • [2] Trial in Progress: A Phase II Window of Opportunity Study of the BCMAxCD3 Bispecific Antibody REGN5458 in Previously Untreated Patients with Symptomatic Multiple Myeloma
    Ferreri, Christopher J.
    Quatela, Steven E.
    Aina, Sean
    Roy, Pourab
    Boyapati, Anita
    Lorenc, Karen Rodriguez
    Kroog, Glenn S.
    Orlowski, Robert Z.
    BLOOD, 2022, 140 : 10129 - 10130
  • [3] Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study
    Bumma, Naresh
    Richter, Joshua
    Brayer, Jason
    Zonder, Jeffrey A.
    Dhodapkar, Madhav
    Shah, Mansi R.
    Hoffman, James E.
    Mawad, Raya
    Maly, Joseph J.
    Lentzsch, Suzanne
    Suvannasankha, Attaya
    Roy, Pourab
    Dey, Jyotirmoy
    Chokshi, Dhruti
    Boyapati, Anita
    Visich, Jenn
    Houvras, Yariv
    Lorenc, Karen Rodriguez
    Kroog, Glenn S.
    Jagannath, Sundar
    BLOOD, 2022, 140 : 10140 - 10141
  • [4] Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific antibody, in a Phase 1/2 study in patients with relapsed/refractory multiple myeloma
    Zonder, Jeffrey
    Richter, Joshua
    Bumma, Naresh
    Brayer, Jason
    Hoffman, James E.
    Bensinger, William I.
    Wu, Ka Lung
    Xu, Linzhi
    Chokshi, Dhruti
    Boyapati, Anita
    Cronier, Damien
    Houvras, Yariv
    Lorenc, Karen Rodriguez
    Kroog, Glenn S.
    Dhodapkar, Madhav V.
    Lentzsch, Suzanne
    Cooper, Dennis
    Jagannath, Sundar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S35 - S35
  • [5] Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma
    Zonder, Jeffrey A.
    Richter, Joshua
    Bumma, Naresh
    Brayer, Jason
    Hoffman, James E.
    Bensinger, William I.
    Wu, Ka Lung
    Xu, Linzhi
    Chokshi, Dhruti
    Boyapati, Anita
    Cronier, Damien
    Houvras, Yariv
    Lorenc, Karen Rodriguez
    Kroog, Glenn S.
    Dhodapkar, Madhav V.
    Lentzsch, Suzanne
    Cooper, Dennis
    Jagannath, Sundar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S406 - S407
  • [6] Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Zonder, Jeffrey A.
    Richter, Joshua
    Bumma, Naresh
    Brayer, Jason
    Hoffman, James E.
    Bensinger, William I.
    Wu, Ka Lung
    Xu, Linzhi
    Chokshi, Dhruti
    Boyapati, Anita
    Sharma, Manish
    Lorenc, Karen Rodriguez
    Kroog, Glenn S.
    Dhodapkar, Mahdav V.
    Lentzsch, Suzanne
    Cooper, Dennis
    Jagannath, Sundar
    BLOOD, 2021, 138
  • [7] REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Madduri, Deepu
    Rosko, Ashley
    Brayer, Jason
    Zonder, Jeffrey
    Bensinger, William I.
    Li, Jingjin
    Xu, Linzhi
    Adriaens, Lieve
    Chokshi, Dhruti
    Zhang, Weijiang
    Boyapati, Anita
    Sharma, Manish
    Seebach, Frank
    Sirulnik, L. Andres
    Weinreich, David M.
    Yancopoulos, George D.
    Dhodapkar, Madhav V.
    Lentzsch, Suzanne
    Cooper, Dennis
    Jagannath, Sundar
    BLOOD, 2020, 136
  • [8] Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
    Cooper, Dennis
    Madduri, Deepu
    Lentzsch, Suzanne
    Jagannath, Sundar
    Li, Jingjin
    Boyapati, Anita
    Adriaens, Lieve
    Chokshi, Dhruti
    Zhu, Min
    Lowy, Israel
    Weinreich, David M.
    Yancopoulos, George D.
    Sharma, Manish
    Karasarides, Maria
    Sternberg, David
    BLOOD, 2019, 134
  • [9] LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.
    Lee, Hans C.
    Bumma, Naresh
    Richter, Joshua Ryan
    Dhodapkar, Madhav V.
    Hoffman, James E.
    Suvannasankha, Attaya
    Zonder, Jeffrey A.
    Shah, Mansi R.
    Lentzsch, Suzanne
    Maly, Joseph J.
    Ye, Jing Christine
    Wu, Ka Lung
    DeVeaux, Michelle
    Chokshi, Dhruti
    Boyapati, Anita
    Hazra, Anasuya
    Rodriguez-Lorenc, Karen
    Kroog, Glenn Scott
    Houvras, Yariv J.
    Jagannath, Sundar
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] REGN5458, a Bispecific BCMAxCD3 T Cell Engaging Antibody, Demonstrates Robust In Vitro and In Vivo Anti-Tumor Efficacy in Multiple Myeloma Models, Comparable to That of BCMA CAR T Cells
    Dilillo, David J.
    Olson, Kara
    Mohrs, Katja
    Meagher, T. Craig
    Bray, Kevin
    Sineshchekova, Olga
    Startz, Thomas
    Retter, Marc
    Godin, Stephen
    Delfino, Frank
    Lin, John
    Smith, Eric
    Thurston, Olin Gavin
    Kirshner, Jessica R.
    BLOOD, 2018, 132